
    
      This is a prospective, Phase I/II multi-center, observational, open-label study in a total of
      210 subjects with metastatic solid tumors, 10 normal controls, 40 with breast cancer, 40 lung
      cancer, 40 gastric and gastroesophageal cancer, 80 other cancer types. All patients with
      confirmed diagnoses will undergo baseline Gallium-68 AIP-301 PET/CT scans to evaluate imaging
      properties and behavior in different tumor types.
    
  